Horizon Pharma, Inc. Announces Third Quarter 2013 Financial Results, Reports Net Revenue of $26.2 Million

Horizon Pharma, Inc. (NASDAQ: HZNP) today provided an update on the Company's business and announced financial results for the third quarter and nine months ended September 30, 2013.

Financial Results

DUEXIS® Highlights

RAYOS® / LODOTRA® Highlights

"We achieved continued acceleration in prescriptions and revenue in the third quarter, with both DUEXIS and RAYOS seeing significant growth in net revenue on a sequential quarter over quarter basis," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma. "This sales growth, along with improvement in the bottom line and cash burn, continues our momentum toward becoming a profitable company."

Help employers find you! Check out all the jobs and post your resume.